Print ISSN: 0027-1446

Online ISSN: 2309-6217

Main Subjects : Hematopathology


Hematological parameters of β-thalassemia Trait in Premarital Screening in Nineveh Province

bassma adnan; Professor Muna Abdulbasit Kashmoola Abdulbasit Kashmoola

Annals of the College of Medicine, Mosul, 2020, Volume 42, Issue 2, Pages 157-161
DOI: 10.33899/mmed.2020.128666.1052

ABSTRACT
Background: β-Thalassaemia syndromes are inherited group of abnormalities of hemoglobin synthesis. These abnormalities characterized by a defect in β-globin genes which may result either in the reduction or absence of one or more of the β-globin chains of hemoglobin. This genetic defect can be homozygous or heterozygous.
Aim of this study was to detect the hematological parameters of β-thalassaemia trait in premarital screening individuals in Nineveh province.
Subjects and Methods: This is a cross sectional study that was performed in Nineveh province in three main centers for premarital screening program. In the period between the 15 November 2019 and the 15 May 2020 a total of 1127 subjects who attend to these centers were screened for carrier conditions of β-thalassemia. Blood samples of the couples were obtained during attendance to the marriage office. Complete blood counts and hemoglobin variant analysis were performed with automated counter and high performance liquid chromatography technique.
Results : Out of 1127, β-thalassaemia trait was diagnosed in 47 subjects, 31 were male (66 %) and 16 were female (34 %). The mean of their hemoglobins was 14.4 g/dl in males, and 12.5 g/dl in females. The mean of mean cell volume and mean cell hemoglobin were 68.3fl and 22.4pg respectively. The mean for HbA2 concentration was 4.9 % and for HbF was 1.2%.
Conclusion: β-thalassaemia trait is usually presented with low MCV and/or low MCH but the accurate and dependable technique in detecting carriers is the use of High Performance Liquid Chromatography (HPLC).

Evaluation of Interleukin- 6 in Lymphoma

Anfal Saleh Mohammed AL-jubory; Sanaa mohammed taib Al- Hayali

Annals of the College of Medicine, Mosul, 2020, Volume 42, Issue 2, Pages 162-168
DOI: 10.33899/mmed.2020.128731.1057

ABSTRACT
Background: Cytokines play a pivotal role in lymphoma ,cytokines either can be produced or exert effects on neoplastic or reactive cells. The elevated level of cytokines can contribute to the clinical and histopathologic alterations associated with malignant lymphoma.
Objectives: to assess the level of IL-6 in newly diagnosed lymphoma patients in relation to their level in normal control subjects and to evaluate the correlation between IL-6 and hemoglobin (Hb), stage of disease and B-symptoms ,age and sex.
Methods: This is a case control study, a total of 40 patients with lymphoma (HL & NHL) who attended private Clincs and hospitals in Mosul city and 40 age and sex matched control were included. A venous blood sample were taken for Complete blood count, Retic and IL-6 level. Enzyme-linked immunosorbent assay(ELISA)was used to determined IL-6 level.
Results: There were a significant difference between the mean level of IL-6 of lymphoma cases and control (p-value=0.00). In the subset of patients with anemia, IL-6 levels inversely correlated with hemoglobin levels (p-value=0.00). There was significant correlation between IL-6 and patients with more advanced stage Ⅲ- IV disease(p-value=0.04). there was positive correlation between IL-6 levels and B-symptoms)p=0.05(
Conclusion: IL-6 level was elevated in lymphoma and it was significantly higher in lymphoma patients .IL-6 plays important role in the development of anemia in lymphoma.The adverse impact of elevated IL-6 is consistent with demonstration of higher level of IL-6 in patients with advanced stage of disease.

Effectiveness of antiplatelet thromboprophylaxis in myeloma patients using immunomodulators in Kurdistan region-Iraq

Rezhen Botany; Ahmed K. Yassin; Firiad Hiwaizi; Abid M. Hassan; Hisham A. Getta; Najmaddin Salih Husen Khoshnaw; Sana D. Jalal; Akram M. Mohammed; Kawa M. Hasan; Dana A. Abdulla; Ameer I.A. Badi; Nassir A. S. Al-Allawi; Banaz M. Safar; Basil K. Abdulla; Rawand P. Shamoon; Truska A. Amin; Zeki A. Mohamed; Ali I. Mohammed; Diveen J. Hussein; Nawsherwan S. Mohammed

Annals of the College of Medicine, Mosul, 2020, Volume 42, Issue 1, Pages 35-41
DOI: 10.33899/mmed.2020.126833.1023

Abstract:

Objective: To evaluate the effectiveness of antiplatelet drugs in preventing thrombosis in multiple myeloma patients treated by immunomodulatory drugs
Methods: The study includes a hundred seventy six patients of symptomatic multiple myeloma treated in hematology unit of three centers in Kurdistan region of Iraq from February 2014 to July 2019. Demographic data were obtained from patient’s file, including the type of immunomodulatory drugs, antiplatelet use, thrombotic events and their site, presence of other comorbidity, and whether the thrombosis was before or after the diagnosis of multiple myeloma.
Background and objectives: Multiple myeloma is a malignant disease that affect both gender and associated with increased risk of thrombosis, one of the effective method of treating myeloma is through using immunomodulatory drugs especially when combined with high dose dexamethasone with in turn boost the risk of thrombosis, in this study we investigate the effect of antiplatelet in preventing thrombosis.
Methods: This is a retrospective study that include 176 cases that are collected from cancer centers at Kurdistan region of Iraq from Feb/2014 to Jul/2019 information gathered through questionnaire.
Results: Regardless the type of therapy in the study sample 11.1% who were taking anti-platelet therapy developed thrombotic attack compared with 46.9% who were not taking the anti-platelets therapy. The incidence of the thrombotic attack among those myeloma patients who used immunomodulatory drugs was 9.6% who were on anti-platelet drugs which is significantly lower than the rate (52%) among patients not taking the anti-platelet drugs.
Conclusions: As multiple myeloma is a malignant disease and treatment with immunomodulatory drugs associated with increased risk of thrombosis, antiplatelet drug is an effective measure when used as a prophylaxis for preventing thrombosis.
Keywords: Multiple myeloma, Thrombosis, Antiplatelet